What is claimed is:

I

- 1. A diagnostic agent comprising an aminocarboxylate ligand complexed with a paramagnetic metal ion wherein a nitrogen atom within said aminocarboxylate is substituted with a substituted aromatic amide group.
- 2. The diagnostic agent of claim 1 wherein said substituted aromatic amide group is of the formula

10

15

25

-
$$(CH_2)_{m}$$
- $C-N-A_1$ - R_2

wherein

 A_1 is $-(CH_2)_m$ '- or a single bond;

 $(CH_2)_{\mathfrak{m}}$ and $(CH_2)_{\mathfrak{m}}'$ may independently be substituted with alkyl or hydroxyalkyl;

alkyl, $-NO_2$, $-NH_2$, $-NHCNHR_{12}$, NCS, $-C-NR_3R_4$, NR_3COR_9 where R_9 is alkyl or hydroxyalkyl, with the proviso that at least one of R_1 and R_2 must be other than hydrogen;

 $$R_{3}$$ and $$R_{4}$$ are independently hydrogen, alkyl, arylalkyl, aryl, alkoxy and hydroxyalkyl;

R₁₂ is hydrogen, alkyl or hydroxyalkyl; R₁₃ is hydrogen, alkyl, arylalkyl, a. [1, alkoxy or hydroxyalkyl; m and m' are independently 1 to 5; and multimeric forms thereof.

3. A diagnostic agent of claim 2 wherein said ligand is of the formula

- 66 -

Ib
$$x_{1}-H_{2}C$$

$$V-R_{5}HC$$

$$CHR_{5}-V$$

$$CHR_{5}-V$$

$$R_{1}$$

$$R_{1}$$

$$R_{1}$$

$$R_{1}$$

$$R_{2}$$

10

5

Ic
$$(X_1-H_2C)_2N-(CH_2)_m-C-N-A_1 \xrightarrow{\stackrel{\scriptstyle O}{\parallel}} R_1^{13}$$

15 Id

$$\begin{array}{c} & & & & & & & & & & & & & & & & \\ & & & & & & & & & & & & & & \\ & & & & & & & & & & & & \\ & & & & & & & & & & \\ & & & & & & & & & \\ & & & & & & & & & \\ & & & & & & & & \\ & & & & & & & & \\ & & & & & & \\ & & & & & \\ & & & & & & \\ & & & & & & \\ & & & & & & \\ & & & & & \\ & & & & & & \\ & & & & & & \\ & & & & & & \\ & & & & & \\ & & & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\$$

wherein m, $\mbox{R}_{13},\mbox{ }\mbox{A}_{1},\mbox{ }\mbox{R}_{1},\mbox{ }\mbox{R}_{2},\mbox{ and }\mbox{R}_{12}$ are as defined in claim 2 and wherein

 X_1 is -COOY₁, PO₃HY₁ or -CONHOY₁;

 Y_1 is a hydrogen atom, a metal ion equivalent and/or a physiologically biocompatible cation of an inorganic or organic base or amino acid;

each R5 is hydrogen or methyl;

R₆ and R₇ together represent a trimethylene group or a tetramethylene group or individually are hydrogen atoms, lower alkyl groups (e.g., 1-8 carbons), phenyl groups, benzyl groups or R₆ is a hydrogen atom and R₇ is $-(CH_2)_p-C_6H_4-W$ -protein where p is 0 or 1, W is -NH-, -NHCOCH₂- or -NHCS-, protein represents a protein residue;

n is 1, 2 or 3;

25

Z is an oxygen atom or a sulfur atom or the group NCH_2X_1 or $NCH_2CH_2OR_8$ wherein X_1 is as defined above and R_8 is $C_{1-8}alkyl$;

V is X_1 or is -CH₂OH, -CONH(CH₂) $_rX_1$ or -COB, wherein X_1 is as defined above, B is a protein or lipid residue, r is an integer from 1 to 12, or if R_5 , R_6 and R_7 are each hydrogen; then both V's together form the group

 $\begin{array}{c|c} \text{CH}_2 \textbf{X}_1 & \text{CH}_2 \textbf{X}_1 \\ & \textbf{I} & \textbf{I} \\ - (\text{CH}_2)_{\,\textbf{w}} - \, \textbf{N} - \text{CH}_2 - \text{CH}_2 - \textbf{N} - (\text{CH}_2)_{\,\textbf{w}} - \end{array}$

where X_1 is as above, w is 1, 2 or 3, provided that at least two of the substituents Y_1 represent metal ion equivalents of an element with an atomic number of 21 to 29, 42, 44 or 57 to 83; from 1 to 4, advantageously 2 or 3, and preferably 2 M's are -OH and the balance independently are $-OR_{10}$, $-NH_2$,

-NHR $_{10}$ and/or NR $_{10}$ R $_{10}$, wherein R $_{10}$ and R $_{10}$, are selected from an organic alkyl radical of up to 18 carbon atoms which may be substituted.

- 68 -

- 4. The diagnostic agent of claim 1 wherein said paramagnetic metal ion is gadolinium.
 - 5. A compound of formula Ia, Ib, Ic or Id as defined in claim 3, including multimers thereof.
 - 6. A compound of the formula

10

15

20

25

wherein

 R_1 and R_2 are each independently hydrogen, S O

alkyl, $-NO_2$, $-NH_2$, $-NHCNHR_{12}$, NCS, $-C-NR_3R_4$ and NR_3COR_9 where R_9 is alkyl or hydroxyalkyl, with the proviso that at least one of R_1 and R_2 must be other than hydrogen;

 R_3 and R_4 are independently hydrogen, alkyl, arylalkyl, aryl, alkoxy and hydroxyalkyl;

 R_{12} is hydrogen, alkyl or hydroxyalkyl; R_{13} is hydrogen, alkyl, arylalkyl, aryl, alkoxy or hydroxyalkyl; m and m' are independently 1 to 5; and multimeric forms thereof.

9. A compound of claim 6 wherein ${\tt R_1}$ and ${\tt R_2}$ 0 ${\tt OH}$ ${\tt I}$ are each ${\tt ^-CNHCH_2-CH-CH_2-OH}$.

10 $\,$ 10. A compound of claim 6 wherein R_1 and R_2 are each

11 A compound of claim 6 having the name 15 10-[2-[[3,5-bis[[(2,3-dihydroxypropyl)amino]-carbonyl]phenyl]amino]-2-oxoethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid.

12. The gadolinium complex of the compound of claim 11.

13. A compound of claim 6 having the name

10-[2-[[3,5-bis-[[[2-hydroxy-1-(hydroxymethy')ethyl]amino]carbonyl]phenylamino]2-oxoethyl]
1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid.

14. The gadolinium complex of the compound of claim 13.

15. A compound of claim 6 having the name
10-[2-[methy1[3,5-bis[[(2-methy1buty1)amino]-

25

carbonyl]phenyl]amino]-2-oxoethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid.

- 16. The gadolinium complex of the compound of claim 15.
- 17. A compound of claim 6 having the name 10-[2-[[4-[[2,3-dihydroxypropyl)amino]carbonyl]-phenyl]amino]-2-oxoethyl-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid.
- $$18$. The gadolinium complex of the compound of 10 <math display="inline">\,$ claim 17.
 - 19. A compound of claim 6 having the name 10-[N-(4-nitrophenyl)acetamido]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid.
- \$20\$. The gadolinium complex of the compound of claim 19.
 - 21. A compound of claim 6 having the name 10-[N-(4-aminophenyl)acetamido]-1,4,7,10-tetraaza-cyclododecane-1,4,7-triacetic acid.
- $$22$. The gadolinium complex of the compound of 20 <math display="inline">\,$ claim 21.
 - 23. A compound of claim 6 having the name 10- [N-(4-(N'-isothiocyanato)phenyl]acetamido]]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid.
- 24. The gadolinium complex of the compound of claim 23.
 - 25. A compound of claim 6 having the name 10-[N-[4-(N'-methylthioureido)phenyl] acetamido] 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid.
- 26. The gadolinium complex of the compound of 30 claim 25.
 - 27. A compound of claim 6 having the name 10-[N-[4-(N',N'-diethylaminothioureido)phenyl]-acetamido]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid.



- 71 -

RA57a

- $28\,.$ The gadolinium complex of the compound of claim $27\,.$
- 29. A compound of claim 6 having the name
 10,10'[[[[(1,2-ethanediyl)diimino]bis(thioxomethyl)diimino]bis(4,1-phenylene)]diimino-bis[1,4,7,10tetraazacyclododecane-1,4,7-triacetic acid].
 - 30. The gadolinium complex of the compound of claim 29.
- 31. A compound of claim 6 having the name
 10 10,10'-[[[[(Thioxomethyl)bis(imino)bis(4,1phenylene)]bis(imino)]bis(2-oxo-2,1-ethanediyl)]1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid.
 - 32. The gadolinium complex of the compound of claim 31.
- 33. A compound of claim 6 having the name 10,10',10''-[[[[[[iminobis(2,1-ethanediy1)triimino]-tris(thioxomethy1)]-triimino]tris-(4,1-phenylene)]-triimino]tris(2-oxo-2,1-ethanediy1)]tris[1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid].
- 34. The gadolinium complex of the compound of claim 33.
 - 35. A compound of claim 6 having the name 10-[2-[[2-(4-nitrophenyl)ethyl]amino]-2-oxoethyl]1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid.
- 25 36. The gadolinium complex of the compound of claim 35.
 - 37. A compound of claim 6 having the name 10-[2-[[3,5-bis[[(2-hydroxyethyl)amino]-carbonyl]-phenyl]amino]-2-oxoethyl]-1,4,7,10-tetra-azacyclododecane-1,4,7-triacetic acid, monosodium
 - salt.

 38. The gadolium complex of the compound of claim 37.

39. A complex, or a pharmaceutically acceptable salt of a complex, of a metal atom and a metal chelating ligand having the formula

wherein

5

15

20

25

 A_1 is $-(\text{CH}_2)_{\,\text{m}}\,'$ - or a single bond; $(\text{CH}_2)_{\,\text{m}} \text{ and } (\text{CH}_2)_{\,\text{m}}\,' \text{ may independently be}$

10 substituted with alkyl or hydroxyalkyl;

 \textbf{R}_1 and \textbf{R}_2 are each independently hydrogen, S \mbox{O}

alkyl, $-NO_2$, $-NH_2$, $-NHCNHR_{12}$, NCS, $-C-NR_3R_4$ and NR_3COR_9 where R_9 is alkyl or hydroxyalkyl, with the proviso that at least one of R_1 and R_2 must be other than hydrogen;

 R_3 and R_4 are independently hydrogen, alkyl, arylalkyl, aryl, alkoxy and hydroxyalkyl;

 R_{12} is hydrogen, alkyl or hydroxyalkyl; R_{13} is hydrogen, alkyl, arylalkyl, aryl, alkoxy or hydroxyalkyl;

m and m' are independently 1 to 5; and multimeric forms thereof.

40. A complex of claim 39 wherein $\ensuremath{\text{R}}_1$ and $\ensuremath{\text{R}}_2$ O

are each $-\overset{\text{\tiny C}}{\text{\tiny C}}-NR_3R_4$ wherein each R_3 group is hydroxyalkyl.

41. A complex of claim 39 wherein R_1 and R_2 \parallel are each $^-\text{C-NR}_3R_4$ wherein each R_3 group is selected OH \parallel from $^-\text{CH}_2\text{-CH-CH}_2\text{-OH}$ and $^-\text{CH}(\text{CH}_2\text{OH})_2$, and wherein each R_4 group is hydrogen.

42. A complex of claim 39 wherein $\rm R_1$ and $\rm R_2$ 0 $$\rm OH$$ $$\rm II$ $$\rm II$ are each -CNHCH2-CH-CH2-OH

 $43\,.$ A complex of claim 39 wherein R_1 and R_2 are each

10

44. A complex of claim 39 wherein said metal atom is of atomic number 56-83.

45. A complex of claim 39 wherein said metal is gadolinium(III).

46. A multimer selected from

$$Q-(CH_2)_{m}-C-N-A_1 \longrightarrow \begin{pmatrix} R_{13} & R_{1} & R_$$

$$Q - (CH_2)_{m} - C - N - A_1$$

$$NH$$

$$R_1 = R_1$$

$$R_1$$

- 74 -

$$Q = (CH_2)_{m} - C - N - A_1 - NH - NH - R_1 \\
NH - R_1 \\
NH - NH - R_1 \\
NH - NH - R_1 \\
NH - NH - C - (CH_2)_{m} - Q$$

$$R_1 \\
NH - NH - R_1 \\
NH - NH - C - (CH_2)_{m} - Q$$

or

5

15

$$X-N$$
 $X-N$
 $X-N$

and wherein Q is an aminocarboxylate ligand and the other variables are as defined in claim 3.

47. A compound of claim 6 having the name 10-[2-[[3,5-bis[[(2-methylbutyl)amino]carbonyl]-phenyl]amino]2-oxoethyl]1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid.

48. The gadolinium complex of the compound of claim 47.

49. A compound of claim 6 having the name 10,10',10'',10''',10'''',10''''-[[[[[[(Nitrilo-

· - 75 -

RA57a

tri-2,1-ethanediyl)tris(nıtrilo)]hexakis-(2,1-ethanedıyl)]hexakıs(imino)hexakis-(carbonothioyl)]hexakis(imino)]hexakıs-(4,1-phenylene)]hexakis-(imino)]hexakis-(2-oxo-2,1-ethanediyl)]hexakis[1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid].

50. The gadolinium complex of the compound of claim 49.